A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone.
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years. Hematologically and cytogenetically, he attained a continuing complete remission, although at one point (9.5 years) at least, after attaining complete remission molecular analysis indicated the presence of minimal residual disease.
Mandigers
C M
CM
University Hospital Nijmegen, Department of Hematology, The Netherlands.
Mensink
E J
EJ
Geurts van Kessel
A
A
van der Plas
D C
DC
Haanen
C
C
Hagemeÿer
A
A
de Witte
T
T
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001769:Blood / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D002066:Busulfan / Q000627:therapeutic use*; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D012074:Remission Induction
D018906:Antineoplastic Agents, Alkylating; D002066:Busulfan